Rybrevant Plus Lazcluze Prevents Resistance in EGFR Lung Cancer
September 8, 2025
Johnson & Johnson has released new findings from the Phase 3 MARIPOSA trial showing that combining RYBREVANT with LAZCLUZE as a first-line treatment significantly lowers